Comtan (entacapone)
- Region
- 🇪🇺 EU
- Active substance
- entacapone
- Company
- Orion Corporation
- Status
- Authorised
- Therapeutic area
- Parkinson Disease
- EU approval
- Tue 22 Sep 1998
- Application
- EMEA/H/C/000171
- ATC
- N04BX02
- Official record
- www.ema.europa.eu
Indication
Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz) Authorised · Orion Corporation
- 🇪🇺 Levodopa/Carbidopa/Entacapone Orion Authorised · Orion Corporation
- 🇪🇺 Stalevo Authorised · Orion Corporation
- 🇪🇺 Entacapone Orion Authorised · Orion Corporation
- 🇪🇺 Comtess Authorised · Orion Corporation
- 🇪🇺 Entacapone Teva Authorised · Teva Pharma B.V.
Follow Comtan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.